To compare the efficacy & safety profile of Febuxostat with Allopurinol in local Pakistani hyperuricemic patients.

Phase 4

Recruiting

• Conditions: Hyperuricemia; Gout; Musculoskeletal - Other muscular and skeletal disorders; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12612000434897
• Lead Sponsor: PharmEvo (Pvt.) Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Subjects are capable of giving informed consent
All male or female adult patients between 18 to 65 years age

All male or female adult patients's Serum Creatinine should be= or > 2 mg/dl

All patients with Asymptomatic = or > 8 mg/dl of Serum Uric Acid

All patients with Symptomatic = or > 6.5 mg/dl of Serum Uric Acid

Physician is the final authority to consider the patient, who is eligible for the clinical trial.

Exclusion Criteria

Known history of allergic with Febuxostat or Allopurinol
Patient with Ischaemic cardiac disease
Acute gout
Renal dysfunction (Serum Creatinine = 4 mg/dL)
Hepatic dysfunction

Study & Design

• Study Type: Interventional
• Study Design: Not specified